Pembrolizumab Activity in Tyrosine Kinase Inhibitor–Refractory Metastatic GIST: A Case Report
- 1USC Norris Comprehensive Cancer Center Keck School of Medicine of the University of Southern California Los Angeles California USA
- 2Department of Internal Medicine Keck School of Medicine of the University of Southern California Los Angeles California USA
- 3Los Angeles General Medical Center Los Angeles California USA
Abstract
Introduction: Gastrointestinal stromal tumors (GISTs) are commonly driven by activating mutations in KIT or PDGFRA. Although sequential tyrosine kinase inhibitors (TKIs) have improved outcomes in advanced disease, acquired resistance is common. Prospective studies of immune checkpoint blockade in GIST have shown limited activity, and immunotherapy is not a standard treatment.
Case Presentation: A man diagnosed at age 57 with epithelioid small‐bowel GIST developed hepatic metastatic disease 7 years after his initial diagnosis. His tumor harbored a primary KIT exon 11 D579del mutation, a secondary KIT exon 17 D820G mutation, and CDKN2A/CDKN2B deletions; available molecular testing reported a low tumor mutational burden (1 mutation/Mb) and microsatellite‐stable disease. After progression or treatment‐limiting toxicity during six TKI regimens, pembrolizumab was initiated on October 28, 2025, when he was 76 years old, and administered intravenously every 3 weeks. The treatment has demonstrated stable disease on CT imaging; cycle 13 was then administered on July 28, 2026. No treatment delays or treatment‐related adverse events were reported through cycle 13.
Conclusion: Pembrolizumab was associated with at least 9 months of disease control in TMB‐low, microsatellite‐stable metastatic GIST after six TKI regimens. Because contemporaneous immune profiling and complete historical dosing data were unavailable, this observation is hypothesis‐generating and does not establish that prior TKI exposure sensitized the tumor to PD‐1 blockade.
Related
- 1189 A phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in adults with relapsed/refractory, advanced/metastatic, immunotherapy-sensitive solid tumors
- 611 Imneskibart + low-dose subcutaneous IL-2 ± nivolumab in doublet checkpoint inhibitor-refractory melanoma: promising activity in an ongoing phase 1/2 study
- 1193 Analysis of a Phase II trial with GT103 in combination with pembrolizumab in refractory, advanced stage non–small cell lung cancer
- Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial
- A Novel ACLY Inhibitor Induces Transcriptional and Metabolic Reprogramming to Overcome Tyrosine kinase inhibitor Resistance in Lymphoma
BibTeX
@article{bandaru2026pembrolizumab,
title = {{Pembrolizumab Activity in Tyrosine Kinase Inhibitor–Refractory Metastatic GIST: A Case Report}},
author = {Neharika Bandaru and Job Shiach and Mark Agulnik},
journal = {Cancer Reports},
year = {2026},
month = nov,
doi = {10.1002/cnr2.70726},
url = {https://doi.org/10.1002/cnr2.70726},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Pembrolizumab Activity in Tyrosine Kinase Inhibitor–Refractory Metastatic GIST: A Case Report
AU - Neharika Bandaru
AU - Job Shiach
AU - Mark Agulnik
PY - 2026
DA - 2026/11/04
JO - Cancer Reports
DO - 10.1002/cnr2.70726
UR - https://doi.org/10.1002/cnr2.70726
AB - Introduction: Gastrointestinal stromal tumors (GISTs) are commonly driven by activating mutations in KIT or PDGFRA. Although sequential tyrosine kinase inhibitors (TKIs) have improved outcomes in advanced disease, acquired resistance is common. Prospective studies of immune checkpoint blockade in GIST have shown limited activity, and immunotherapy is not a standard treatment. Case Presentation: A man diagnosed at age 57 with epithelioid small‐bowel GIST developed hepatic metastatic disease 7 years after his initial diagnosis. His tumor harbored a primary KIT exon 11 D579del mutation, a secondary KIT exon 17 D820G mutation, and CDKN2A/CDKN2B deletions; available molecular testing reported a low tumor mutational burden (1 mutation/Mb) and microsatellite‐stable disease. After progression or treatment‐limiting toxicity during six TKI regimens, pembrolizumab was initiated on October 28, 2025, when he was 76 years old, and administered intravenously every 3 weeks. The treatment has demonstrated stable disease on CT imaging; cycle 13 was then administered on July 28, 2026. No treatment delays or treatment‐related adverse events were reported through cycle 13. Conclusion: Pembrolizumab was associated with at least 9 months of disease control in TMB‐low, microsatellite‐stable metastatic GIST after six TKI regimens. Because contemporaneous immune profiling and complete historical dosing data were unavailable, this observation is hypothesis‐generating and does not establish that prior TKI exposure sensitized the tumor to PD‐1 blockade.
SN - 2573-8348
ER -